Supervised in the office
Treatment takes place in the office under the supervision of a healthcare provider, in a supportive setting rather than on your own.
Services
SPRAVATO® Treatment
SPRAVATO® (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression and certain adults with major depressive disorder. It offers a different approach for patients who have not experienced adequate relief from traditional antidepressant treatments.
How it is given
Given in the office, then monitored
SPRAVATO is administered in the office under the supervision of a healthcare provider. Patients self-administer the nasal spray and are monitored for at least two hours afterward for safety.
You administer the spray
Patients self-administer the nasal spray while a clinician is present for the visit.
At least two hours of monitoring
After the dose, you are monitored for at least two hours so the visit stays focused on safety.
The schedule
How the schedule usually unfolds
Treatment typically begins twice weekly for four weeks, followed by weekly treatments and, when appropriate, treatments every one to two weeks based on individual response.
01
Twice weekly for four weeks
The first phase is typically two treatments a week for four weeks.
02
Then weekly
After those four weeks, treatment usually continues once a week.
03
Then every one to two weeks
When appropriate, visits may move to every one to two weeks, based on individual response.
Our care
Support throughout treatment
Our practice provides a supportive, closely monitored environment throughout treatment and works with each patient to determine whether SPRAVATO may be an appropriate option.
Who this may be for
- Adults with treatment-resistant depression
- Certain adults with major depressive disorder
- Patients who have not experienced adequate relief from traditional antidepressant treatments
Call, text, or email for a consultation.
Schedule your consultation
You are not alone, and you do not have to carry it all by yourself.